Pfizer (NYSE:PFE) Shares Up 2.6% – Time to Buy?

Shares of Pfizer Inc. (NYSE:PFE) traded up 2.6% during trading on Monday . The company traded as high as $27.82 and last traded at $27.7510. 45,805,413 shares changed hands during mid-day trading, a decline of 0% from the average session volume of 45,827,262 shares. The stock had previously closed at $27.04.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Investor buying tied to renewed interest in Pfizer’s GLP?1 program — coverage notes that PFE remains on Jim Cramer’s list of GLP?1/weight?loss picks and that shares have risen since his “pass” comment, reflecting momentum around Pfizer’s monthly GLP?1 candidate and retail attention. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: High retail interest — Zacks reports Pfizer among the most?searched stocks on its site recently, a sign of increased retail attention that can amplify price moves and liquidity around news events. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Positive Sentiment: Long?term bullish commentary — The Motley Fool publishes a bullish take arguing Pfizer’s diversified portfolio and ability to pivot support a long?term buy case despite being behind leaders in GLP?1s. This helps sentiment among buy?and?hold investors. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Income appeal — Pfizer is listed among large?cap stocks with high dividends, which supports demand from income investors and can reduce volatility. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Analyst consensus remains lukewarm — MarketBeat/analyst tallies show a consensus “Hold” with more holds and sells than buys, indicating limited near?term upgrades to propel a sustained rally. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Neutral Sentiment: Technical/volume context — Today’s price moved higher but on volume below the stock’s 3?month average, so follow?through will depend on whether higher attention (searches/coverage) sustains buying interest.
• Negative Sentiment: Competitive and technology risks — Sector?level moves such as Eli Lilly’s large AI/drug?discovery deal underscore accelerating competition and technological differentiation among peers, which could pressure Pfizer’s market share and long?term drug pipeline competitiveness. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. TD Cowen restated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Bank of America cut their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the company a “positive” rating in a research note on Tuesday, March 17th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Performance

The business’s fifty day moving average is $26.84 and its 200-day moving average is $25.70. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company has a market cap of $157.80 billion, a PE ratio of 20.41 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of PFE. Triad Wealth Partners LLC lifted its position in shares of Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares in the last quarter. ETF Store Inc. increased its holdings in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Mattern Wealth Management LLC raised its stake in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares during the period. Pines Wealth Management LLC lifted its holdings in Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Peak Asset Management LLC lifted its holdings in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.